Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Giralt

Showing results (241-250 of 242) with videos related to

Pageof 25
Sort By:
You have reached the last page of results.This site can display upto 242 results.
Haematologica|December 20, 1999
Stage, percentage of basophils at diagnosis, hematologic response within six months, cytogenetic response in the first year: the main prognostic variables affecting outcome in patients with chronic myeloid leukemia in chronic phase treated with interferon-alpha. Results of the CML89 trial of the Spanish Collaborative Group on interferon-alpha2a and CMLJ L Steegmann, J Odriozola, F Rodriguez-Salvanés, et al.
Journal of Inherited Metabolic Disease|November 8, 2003
The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statementT M Cox, J M F G Aerts, G Andria, et al.
Pageof 25

Showing results (241-250 of 242) with videos related to

Sort By:
Pageof 25
You have reached the last page of results.This site can display upto 242 results.
Haematologica|December 20, 1999
Stage, percentage of basophils at diagnosis, hematologic response within six months, cytogenetic response in the first year: the main prognostic variables affecting outcome in patients with chronic myeloid leukemia in chronic phase treated with interferon-alpha. Results of the CML89 trial of the Spanish Collaborative Group on interferon-alpha2a and CMLJ L Steegmann, J Odriozola, F Rodriguez-Salvanés, et al.
Journal of Inherited Metabolic Disease|November 8, 2003
The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statementT M Cox, J M F G Aerts, G Andria, et al.
Pageof 25